Selinexor
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- University of Chicago Medicine
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 636
- NCT Identifier
- NCT02199665
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.